Literature DB >> 29739756

Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells.

Molly J Carroll1, Kaitlin C Fogg1, Harin A Patel1, Harris B Krause1, Anne-Sophie Mancha1,2, Manish S Patankar3,4, Paul S Weisman5, Lisa Barroilhet3,4, Pamela K Kreeger6,3,4,7.   

Abstract

Peritoneal metastasis of high-grade serous ovarian cancer (HGSOC) occurs when tumor cells suspended in ascites adhere to mesothelial cells. Despite the strong relationship between metastatic burden and prognosis in HGSOC, there are currently no therapies specifically targeting the metastatic process. We utilized a coculture model and multivariate analysis to examine how interactions between tumor cells, mesothelial cells, and alternatively-activated macrophages (AAM) influence the adhesion of tumor cells to mesothelial cells. We found that AAM-secreted MIP-1β activates CCR5/PI3K signaling in mesothelial cells, resulting in expression of P-selectin on the mesothelial cell surface. Tumor cells attached to this de novo P-selectin through CD24, resulting in increased tumor cell adhesion in static conditions and rolling underflow. C57/BL6 mice treated with MIP-1β exhibited increased P-selectin expression on mesothelial cells lining peritoneal tissues, which enhanced CaOV3 adhesion ex vivo and ID8 adhesion in vivo Analysis of samples from patients with HGSOC confirmed increased MIP-1β and P-selectin, suggesting that this novel multicellular mechanism could be targeted to slow or stop metastasis in HGSOC by repurposing anti-CCR5 and P-selectin therapies developed for other indications.Significance: This study reports novel insights on the peritoneal dissemination occurring during progression of ovarian cancer and has potential for therapeutic intervention.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/13/3560/F1.large.jpg Cancer Res; 78(13); 3560-73. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29739756      PMCID: PMC6030435          DOI: 10.1158/0008-5472.CAN-17-3341

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.

Authors:  R P Negus; G W Stamp; J Hadley; F R Balkwill
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Selectins: initiators of leucocyte adhesion and signalling at the vascular wall.

Authors:  Rodger P McEver
Journal:  Cardiovasc Res       Date:  2015-05-20       Impact factor: 10.787

Review 3.  Chemokine: receptor structure, interactions, and antagonism.

Authors:  Samantha J Allen; Susan E Crown; Tracy M Handel
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

4.  Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

Authors:  Hilary A Kenny; Madhu Lal-Nag; Erin A White; Min Shen; Chun-Yi Chiang; Anirban K Mitra; Yilin Zhang; Marion Curtis; Elizabeth M Schryver; Sam Bettis; Ajit Jadhav; Matthew B Boxer; Zhuyin Li; Marc Ferrer; Ernst Lengyel
Journal:  Nat Commun       Date:  2015-02-05       Impact factor: 14.919

5.  P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism.

Authors:  Tao Xu; Lei Zhang; Zhen H Geng; Hai-Bo Wang; Jin-Tao Wang; Ming Chen; Jian-Guo Geng
Journal:  Cell Adh Migr       Date:  2007-07-05       Impact factor: 3.405

6.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis.

Authors:  Shicheng Su; Qiang Liu; Jingqi Chen; Jianing Chen; Fei Chen; Chonghua He; Di Huang; Wei Wu; Ling Lin; Wei Huang; Jin Zhang; Xiuying Cui; Fang Zheng; Haiyan Li; Herui Yao; Fengxi Su; Erwei Song
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

Review 7.  The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.

Authors:  Bianca Cheaib; Aurélie Auguste; Alexandra Leary
Journal:  Chin J Cancer       Date:  2015-01

8.  Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.

Authors:  Silke Reinartz; Tim Schumann; Florian Finkernagel; Annika Wortmann; Julia M Jansen; Wolfgang Meissner; Michael Krause; Anne-Marie Schwörer; Uwe Wagner; Sabine Müller-Brüsselbach; Rolf Müller
Journal:  Int J Cancer       Date:  2013-07-19       Impact factor: 7.396

9.  Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.

Authors:  Thorsten Hagemann; Julia Wilson; Frances Burke; Hagen Kulbe; Ninfeng Fiona Li; Annette Plüddemann; Kellie Charles; Siamon Gordon; Frances R Balkwill
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

10.  Human breast cancer cells educate macrophages toward the M2 activation status.

Authors:  Sofia Sousa; Régis Brion; Minnamaija Lintunen; Pauliina Kronqvist; Jouko Sandholm; Jukka Mönkkönen; Pirkko-Liisa Kellokumpu-Lehtinen; Susanna Lauttia; Olli Tynninen; Heikki Joensuu; Dominique Heymann; Jorma A Määttä
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

View more
  26 in total

1.  Ovarian Cells Have Increased Proliferation in Response to Heparin-Binding Epidermal Growth Factor as Collagen Density Increases.

Authors:  Kaitlin C Fogg; Carine M Renner; Hannah Christian; Alyssa Walker; Leilani Marty-Santos; Aisha Khan; Will R Olson; Carl Parent; Andrea O'Shea; Deneen M Wellik; Paul S Weisman; Pamela K Kreeger
Journal:  Tissue Eng Part A       Date:  2020-06-25       Impact factor: 3.845

2.  Processing and Analysis of Ascites.

Authors:  Hannah M Micek; Molly J Carroll; Lisa Barroilhet; Pamela K Kreeger
Journal:  Methods Mol Biol       Date:  2022

3.  Bioengineering Approaches to Improve Gynecological Cancer Outcomes.

Authors:  Ali Abbaspour; Andrea L Casillas; Stephanie M McGregor; Pamela K Kreeger
Journal:  Curr Opin Biomed Eng       Date:  2022-03-30

4.  Confocal Imaging of Single-Cell Signaling in Orthotopic Models of Ovarian Cancer.

Authors:  Dylan O Matvey; Thomas S C Ng; Miles A Miller
Journal:  Methods Mol Biol       Date:  2022

5.  Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Authors:  Peter C Hart; Preety Bajwa; Hilary A Kenny
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway.

Authors:  Kaitlin C Fogg; Will R Olson; Jamison N Miller; Aisha Khan; Carine Renner; Isaac Hale; Paul S Weisman; Pamela K Kreeger
Journal:  Cancer Lett       Date:  2019-05-24       Impact factor: 8.679

Review 7.  Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model.

Authors:  Eric N Horst; Michael E Bregenzer; Pooja Mehta; Catherine S Snyder; Taylor Repetto; Yang Yang-Hartwich; Geeta Mehta
Journal:  Acta Biomater       Date:  2021-04-30       Impact factor: 10.633

Review 8.  Models for measuring metabolic chemical changes in the metastasis of high grade serous ovarian cancer: fallopian tube, ovary, and omentum.

Authors:  Hannah Lusk; Joanna E Burdette; Laura M Sanchez
Journal:  Mol Omics       Date:  2021-12-06

Review 9.  The Many Microenvironments of Ovarian Cancer.

Authors:  Hannah M Micek; Mike R Visetsouk; Andrew J Fleszar; Pamela K Kreeger
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.

Authors:  Yue Lu; Alphonsus H C Ng; Frances E Chow; Richard G Everson; Beth A Helmink; Michael T Tetzlaff; Rohit Thakur; Jennifer A Wargo; Timothy F Cloughesy; Robert M Prins; James R Heath
Journal:  Nat Commun       Date:  2021-06-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.